A Transformative Quarter
Unlocking Value & Returning Capital to Shareholders
With a Focus on Innovation, Clinical Progress & Long-Term Growth
The second quarter of 2026 marked a defining milestone for Cumberland Pharmaceuticals. With the successful completion of our Strategic Transaction, we entered a new chapter as an innovation-focused biopharmaceutical company dedicated to advancing new medicines for patients with significant unmet medical needs. We also strengthened our financial position, returned capital to shareholders through a special dividend and continued advancing our clinical pipeline.
During the quarter, we shared several exciting company updates, including:
- We successfully completed our Strategic Transaction integrating our commercial brands and organization with Apotex Health. As a results we have significantly strengthened our balance sheet, reduced operating expensea and sharpening our focus on advancing our pipeline of differentiated medicines.
- We also announced and funded a special dividend to return capital to shareholders while maintaining the resources needed to support our long-term strategy.
- At the Parent Project Muscular Dystrophy Annual Conference, we presented new biomarker findings from our study evaluating ifetroban in patients with Duchenne muscular dystrophy-associated cardiomyopathy. The additional data further support ifetroban’s potential to preserve cardiac function in patients living with this deadly disease.
- We announced positive results from our clinical collaboration with Vanderbilt Health evaluating ifetroban as a potential therapy to prevent cancer metastasis in patients with high-risk solid tumors. The study met its primary safety endpoint. The results also provided encouraging efficacy signals, including fewer patients experiencing metastatic recurrence and no metastasis-related deaths in the ifetroban treatment arm. These findings support continued development of ifetroban as a potential first-in-class therapy targeting the metastatic process.
As we move forward, we remain focused on executing our strategy, advancing our ifetroban clinical programs and building the next generation of growth for Cumberland. We appreciate the continued support of our shareholders, employees and partners as we advance innovative therapies to improve patient care.